Arista for ALT Donor Sites to Reduce Drain Output
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02477774|
Recruitment Status : Recruiting
First Posted : June 23, 2015
Last Update Posted : February 24, 2020
This is a single-blinded multi-institutional randomized controlled trial to evaluate the effectiveness of Arista hemostatic matrix powder (Arista® AH, C. R. Bard, Inc. Davol, Warwick, RI) in reducing drainage output in anterolateral thigh (ALT) free flap donor sites. Increased drainage from donor sites can lead to seroma formation with possible secondary infection, delayed hospital discharge, and additional home care needs for drain care. Arista is an inert plant based absorbable surgical hemostatic powder that can be easily applied to broad surgical fields to reduce bleeding and seroma rates. Therefore, its application to free flap donor sites may bear significant potential benefit.
Specific Aim 1: The main hypothesis of the study is that the use of Arista in anterolateral thigh (ALT) free flap donor sites prior to closure will reduce postoperative drain outputs and time to drain removal compared to ALT donor sites closed without Arista.
Specific Aim 2: This study will also evaluate the secondary hypotheses that Arista will reduce postoperative ALT donor site seromas and patient hospital length of stay.
|Condition or disease||Intervention/treatment||Phase|
|Seroma||Device: ARISTA||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Multi-Institutional Randomized Controlled Trial Evaluating Use of Arista Absorbable Surgical Hemostatic Powder in Anterolateral Thigh Donor Sites|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||July 2021|
|Estimated Study Completion Date :||July 2021|
Arista to ALT donor site
According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
No Intervention: Control
No Arista to ALT donor site
- total drain output [ Time Frame: 1-14 days after Surgery ]The primary outcome analyzed in this study will be total drain output (mL) in an effort to determine if the addition of Arista to the wound bed decreases overall wound drainage and drain output.
- Development of ALT donor site seroma. [ Time Frame: 30 days postoperative ]ALT donor site will be evaluated for seroma
- Timing to Drain Removal [ Time Frame: 30 days postoperative ]Given that drain output influences time of drain removal, assessment will be made to determine if timing of drain removal differs between groups.
- Hospital Length of Stay [ Time Frame: 30 days postoperative ]Will eval hospital length of stay for both groups
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02477774
|United States, California|
|University of California San Francisco||Recruiting|
|San Francisco, California, United States, 94115|
|Contact: Rahul Seth, MD Rahul.email@example.com|
|Principal Investigator:||Rahul Seth, MD||University of California, San Francisco|